Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SHH | Q15465 | 1/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624919 | 0.90 | MAPT (0.45) | MAPTGRM4HDAC6 | |
| SCHEMBL1624603 | 0.88 | MEN1 (0.43) | SMO | |
| SCHEMBL1624411 | 0.85 | RAB9A (0.60) | MAPT | |
| SCHEMBL1625365 | 0.85 | SMPD3 (0.44) | MAPTGRM4HDAC6PDE4DSMO | |
| SCHEMBL1624600 | 0.84 | MAOB (0.50) | MAPTSMO | |
| SCHEMBL1624851 | 0.84 | MAPT (0.43) | MAPT | |
| SCHEMBL1624299 | 0.84 | KCNK3 (0.50) | MAPT | |
| SCHEMBL1625036 | 0.83 | NPC1 (0.56) | MAPT | |
| SCHEMBL1625226 | 0.83 | MEN1 (0.48) | ALBHTR1ASLC6A2PDE4AOPRM1 | |
| SCHEMBL1625099 | 0.82 | MAPT (0.52) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | claimed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | claimed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | claimed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4300/4885GRM4 704/4885HDAC6 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.